Search results for "immune"

showing 10 items of 3935 documents

Immunological features of coronavirus disease 2019 in patients with cancer.

2020

Background Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has caused a major pandemic. Patients with cancer are at higher risk of severe COVID-19. We aimed to describe and compare the immunological features of cancer patients hospitalised for COVID-19 or other concomitant, cancer-related illness. Methods In this prospective study, the clinical and immunological characteristics of 11 cancer patients with COVID-19 and 11 non–COVID-19 cancer patients hospitalised in the same unit at the same period for other medical issues were analysed. We also used 10 healthy volunteers as controls. Peripheral immune parameters were analysed using multiparamet…

0301 basic medicineCD4-Positive T-LymphocytesMaleCancer ResearchTime Factors[SDV]Life Sciences [q-bio]Pneumonia ViralHuman leukocyte antigenCD8-Positive T-LymphocytesProcalcitonin03 medical and health sciencesBetacoronavirus0302 clinical medicineImmune systemNeoplasmsMedicineCytotoxic T cellHumansProspective StudiesPandemicsOriginal ResearchCancerAgedbusiness.industrySARS-CoV-2MonocyteCancerCOVID-19medicine.disease3. Good healthImmunomonitoring[SDV] Life Sciences [q-bio]030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunologyTumor necrosis factor alphaFemaleFrancebusinessCoronavirus InfectionsCD8T-Lymphocytes CytotoxicEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Increased expression of interleukin-22 in patients with giant cell arteritis

2017

Objectives GCA is characterized by arterial remodelling driven by inflammation. IL-22 is an attractive cytokine which acts at the crosstalk between immune and stromal cells. We hypothesized that IL-22 might be induced in GCA and might be involved in disease pathogenesis. Methods Patients subjected to temporal artery biopsies (TABs) naive from therapy were enrolled: 27 biopsy-proven GCA, 8 biopsy-negative GCA, 21 biopsy-negative non-GCA patients. Expression of IL-22 was determined in TABs by immunohystochemistry, in plasma by ELISA, in peripheral blood mononuclear cells by real-time PCR and flow cytometry. Effects of IL-22 on viability and gene expression of primary cultures obtained from TA…

0301 basic medicineCD4-Positive T-LymphocytesMalearterial remodelling; autoimmunity; giant cell arteritis; inflammation; interleukin-22; pathogenesismedicine.medical_treatmentMessengerInterleukin 220302 clinical medicineimmune system diseasesarterial remodelling; autoimmunity; giant cell arteritis; inflammation; interleukin-22; pathogenesis; Aged; Aged 80 and over; CD4-Positive T-Lymphocytes; Calcium Ionophores; Carcinogens; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Giant Cell Arteritis; Humans; Immunohistochemistry; In Vitro Techniques; Interleukins; Ionomycin; Leukocytes Mononuclear; Male; RNA Messenger; Real-Time Polymerase Chain Reaction; Temporal Arteries; Tetradecanoylphorbol Acetate80 and overLeukocytesPharmacology (medical)skin and connective tissue diseasesAged 80 and overIonomycinpathogenesisautoimmunityInterleukinFlow CytometryImmunohistochemistryTemporal ArteriesCalcium IonophoresCytokinecardiovascular systemTetradecanoylphorbol AcetateFemalemedicine.symptomgiant cell arteritiStromal cellMononuclearGiant Cell ArteritisInflammationEnzyme-Linked Immunosorbent AssayIn Vitro TechniquesReal-Time Polymerase Chain ReactionPeripheral blood mononuclear cellarterial remodelling03 medical and health sciencesRheumatologymedicineHumansViability assayRNA Messengercardiovascular diseasesAged030203 arthritis & rheumatologybusiness.industryInterleukinsinterleukin-22medicine.diseaseGiant cell arteritis030104 developmental biologyinflammationCase-Control StudiesImmunologyCarcinogensLeukocytes MononuclearRNAbusiness
researchProduct

The iNOS Activity During an Immune Response Controls the CNS Pathology in Experimental Autoimmune Encephalomyelitis

2019

Inducible nitric oxide synthase (iNOS) plays a critical role in the regulation of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Previous studies have shown that iNOS plays pathogenic as well as regulatory roles in MS and EAE. However, how does iNOS alters the pathophysiology of the central nervous system (CNS) in neuronal autoimmunity is not clearly understood. In the present work, we show that treatment of mice with L-NAME, an iNOS inhibitor, during the antigen-priming phase primarily alters brain pathology, while in the subsequent effector phase of the immune response, the spinal cord is involved. Inhibition of iNOS during the priming phase of the immune res…

0301 basic medicineCD4-Positive T-LymphocytesPathologyexperimental autoimmune encephalomyelitisNitric Oxide Synthase Type IIApoptosismedicine.disease_causeAutoimmunityMice0302 clinical medicineImmunology and AllergyEnzyme InhibitorsOriginal ResearchMice KnockoutbiologyExperimental autoimmune encephalomyelitisautoimmunityCell DifferentiationNitric oxide synthaseOligodendrogliamedicine.anatomical_structureNG-Nitroarginine Methyl EsterIntegrin alpha Mlcsh:Immunologic diseases. Allergymedicine.medical_specialtyEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisLymphoid TissueCentral nervous systemImmunology03 medical and health sciencesInterferon-gammaImmune systemmedicineAnimalsHumansNOS2−/− neuroinflammationNeuroinflammationbusiness.industryMultiple sclerosisinducible nitric oxide synthaseDendritic Cellsmedicine.diseasecentral nervous systemMice Inbred C57BL030104 developmental biologybiology.proteinbusinesslcsh:RC581-607030215 immunologyGranulocytesFrontiers in Immunology
researchProduct

Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and…

2017

Incidence and prevalence of inflammatory liver diseases has increased over the last years, but therapeutic options are limited. Pregnancy induces a state of immune tolerance, which can result in spontaneous improvement of clinical symptoms of certain autoimmune diseases including autoimmune hepatitis (AIH). We investigated the immune-suppressive mechanisms of the human pregnancy hormone, chorionic gonadotropin (hCG), in the liver. hCG signaling activates silent mating type information regulation 2 homolog 1 (SIRT1), which deacetylates forkhead box o3 (FOXO3a), leading to repression of proapoptotic gene expression, because the immunosuppressive consequence attributed to the absence of caspas…

0301 basic medicineCD4-Positive T-Lymphocytesmedicine.medical_specialtymedicine.drug_classInflammationAutoimmune hepatitisChorionic GonadotropinSensitivity and SpecificityHuman chorionic gonadotropinImmune tolerance03 medical and health sciencesMiceRandom Allocation0302 clinical medicineImmune systemSirtuin 1Internal medicinemedicineJournal ArticleAnimalsHumansComparative StudyCells CulturedMice Inbred BALB CHepatologybusiness.industryCaspase 3Forkhead Box Protein O3Hepatologymedicine.diseaseDisease Models AnimalHepatitis Autoimmune030104 developmental biologyEndocrinology030220 oncology & carcinogenesisImmunologyHepatocytesFemaleGonadotropinmedicine.symptombusinessHormoneSignal TransductionHepatology
researchProduct

Toll like receptor mediated immune stimulation can be visualized in vivo by [ 18 F]FDG-PET

2016

Abstract Introduction High uptake of [ 18 F]-2-fluorodeoxyglucose ([ 18 F]FDG) by inflammatory cells is a frequent cause of false positive results in [ 18 F]FDG-positron-emission tomography (PET) for cancer diagnostics. Similar to cancer cells, immune cells undergo significant increases in glucose utilization following activation, e.g., in infectious diseases or after vaccination during cancer therapy. The aim of this study was to quantify certain immune effects in vitro and in vivo by [ 18 F]FDG-PET after stimulation with TLR ligands and specific antibodies. Methods In vivo [ 18 F]FDG-PET/magnetic resonance imaging (MRI) and biodistribution was performed with C57BL/6 mice immunized with Cp…

0301 basic medicineCD86Cancer ResearchPathologymedicine.medical_specialtyB-cell receptorCD28Biology03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureImmune systemIn vivo030220 oncology & carcinogenesisCancer cellmedicineCancer researchMolecular MedicineRadiology Nuclear Medicine and imagingLymph nodeCD80Nuclear Medicine and Biology
researchProduct

Case report : partial uniparental disomy unmasks a novel recessive mutation in the LYST gene in a patient with a severe phenotype of Chediak-Higashi …

2021

Síndrome de Chédiak-Higashi; LYST; Disomia uniparental Síndrome de Chédiak-Higashi; LYST; Disomía uniparental Chédiak-Higashi syndrome; LYST; Uniparental disomy Chédiak-Higashi syndrome (CHS) is a rare autosomal recessive (AR) immune disorder that has usually been associated to missense, nonsense or indels mutations in the LYST gene. In this study, we describe for the first time the case of a CHS patient carrying a homozygous mutation in the LYST gene inherited as a result of a partial uniparental isodisomy (UPiD) of maternal origin. Sanger sequencing of the LYST cDNA and single nucleotide polymorphism (SNP)-arrays were performed to identify the causative mutation and to explain the molecul…

0301 basic medicineCHSLYSTCase ReportHemophagocytic lymphohistiocytosis030105 genetics & hereditymedicine.disease_causeLoss of heterozygosityExonCh&#233diak-Higashi syndromeImmunology and AllergyMissense mutation:Genetic Phenomena::Genetic Phenomena::Inheritance Patterns::Genes Recessive [PHENOMENA AND PROCESSES]Genetics:fenómenos genéticos::fenómenos genéticos::patrones de herencia::genes recesivos [FENÓMENOS Y PROCESOS]MutationPrimary immunodeficiencySistema inmune - Enfermedades - Diagnóstico.Loss of heterozygosityChédiak-Higashi Síndrome de - Diagnóstico.:enfermedades del sistema inmune::síndromes de inmunodeficiencia::disfunción bactericida del fagocito::síndrome de Chediak-Higashi [ENFERMEDADES]Uniparental disomyImmune system - Diseases - Diagnosis.Chromosome abnormalities.loss of heterozygositySNP array:fenómenos genéticos::variación genética::mutación::aberraciones cromosómicas::disomía uniparental [FENÓMENOS Y PROCESOS]lcsh:Immunologic diseases. AllergyAnomalías y malformaciones cromosómicas.disomia uniparentaluniparental disomy:Immune System Diseases::Immunologic Deficiency Syndromes::Phagocyte Bactericidal Dysfunction::Chediak-Higashi Syndrome [DISEASES]ImmunologyChédiak-Higashi syndromeSingle-nucleotide polymorphismBiologyprimary immunodeficiency03 medical and health sciencesMalalties immunològiquesmedicineGenetic disorders - Diagnosis.Béguez-Chédiak-Higashi syndrome - Diagnosis.Uniparental disomymedicine.diseaseSNP-array030104 developmental biologyAnomalies cromosòmiquesUniparental Isodisomyhemophagocytic lymphohistiocytosisEnfermedades genéticas - Diagnóstico.lcsh:RC581-607:Genetic Phenomena::Genetic Variation::Mutation::Chromosome Aberrations::Uniparental Disomy [PHENOMENA AND PROCESSES]
researchProduct

The immunological implication of the new vitamin D metabolism

2018

Vitamin D is a neuro-hormone regulating calcium-phosphate homeostasis, cell proliferation, and immunomodulation. exogenous and endogenous Vitamin D is inactive, and two hydroxylations are required to produce the active hormone. The first hydroxylation is unique to the liver, while the second step occurs in kidney, brain, lung, prostate, placenta, and immune cells. Kidney-derived calcitriol regulates calcium homeostasis. active hormone produced by brain and immune cells mediates immune system response; lung calcitriol is involved in fighting respiratory tract infections; finally, prostate and placenta Vitamin D regulates cells growth and proliferation within such tissues. immune modulation b…

0301 basic medicineCalcitriolImmunologylcsh:Medicinevitamin Dmedicine.disease_causeimmunomodulationCalcitriol receptorAutoimmunity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemCYPsCYPVitamin D and neurologyImmunology and AllergyMedicineVDRCalcium metabolismReview PaperInnate immune systembusiness.industryautoimmunitylcsh:R030104 developmental biologychemistryImmunologybusinessCholecalciferol030217 neurology & neurosurgerymedicine.drugCentral European Journal of Immunology
researchProduct

Time for a “Plan B” in Peritoneal Metastatic Disease

2019

Abstract Peritoneal involvement in cancer is the harbinger of a particularly unfavorable prognosis. The peritoneal cavity microenvironment is skewed toward immunoregulatory conditions promoted by macrophage populations and innate-like B-1 B cells, which provide immune privilege to malignant cell foci. In this issue of Cancer Research, Haro and colleagues demonstrate that triggering innate IgM-mediated B-1a immune responses via pathogen- or danger-associated molecular pattern recognition exerts antitumor effects on peritoneal metastases by inducing classical complement cascade activation. Exploitation of innate B-1 humoral responses and noncellular immunity is a promising strategy to counter…

0301 basic medicineCancer Research03 medical and health sciencesPeritoneal NeoplasmPeritoneal cavity0302 clinical medicineImmune systemImmune privilegeImmunityTumor MicroenvironmentMedicineMacrophagePeritoneal CavityPeritoneal NeoplasmsB-Lymphocyte SubsetTumor microenvironmentbusiness.industryCancermedicine.diseaseImmunity Innate030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchbusinessHumanCancer Research
researchProduct

Checkpoint Inhibition in Non-Hodgkin's Lymphoma.

2017

As patients continue to die from malignant lymphoma, novel treatment options continue to be warranted. To successfully grow and spread, tumor cells need to escape the immune system; therefore, the augmentation or restoration of immune effectors against the malignant cell could be of great value, as shown, e.g., for allogeneic transplantation. A deepened understanding of the regulation of activation and inhibition of the T cell-based effector mechanisms has led to the development of drugs that are able to modify specific checkpoints of this system and thereby raise an immune response against tumor cells. With dramatic responses observed in Hodgkin's disease (HD), interest has risen to explor…

0301 basic medicineCancer ResearchAllogeneic transplantationT cellT-LymphocytesAntineoplastic AgentsDisease03 medical and health sciences0302 clinical medicineImmune systemhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineEffectorbusiness.industryLymphoma Non-HodgkinAntibodies MonoclonalHematologymedicine.diseaseIpilimumabLymphomaNon-Hodgkin's lymphoma030104 developmental biologymedicine.anatomical_structureNivolumabOncology030220 oncology & carcinogenesisCancer researchTumor EscapePrimary mediastinal B-cell lymphomabusinessRituximabOncology research and treatment
researchProduct

Extracellular vesicles as miRNA nano-shuttles : dual role in tumor progression

2018

[EN] Tumor-derived extracellular vesicles (EVs) have a pleiotropic role in cancer, interacting with target cells of the tumor microenvironment, such as fibroblasts, immune and endothelial cells. EVs can modulate tumor progression, angiogenic switch, metastasis, and immune escape. These vesicles are nano-shuttles containing a wide spectrum of miRNAs that contribute to tumor progression. MiRNAs contained in extracellular vesicles (EV-miRNAs) are disseminated in the extracellular space and are able to influence the expression of target genes with either tumor suppressor or oncogenic functions, depending on both parental and target cells. Metastatic cancer cells can balance their oncogenic pote…

0301 basic medicineCancer ResearchAngiogenic SwitchLung-CancerBIOLOGIA CELULARMessenger-RNAsSuppressor-CellsDendritic cellsMetastasisLiquid biopsies03 medical and health sciencesExtracellular VesiclesImmune systemSettore BIO/13 - Biologia ApplicatamicroRNAMedicineHumansNanotechnologyPharmacology (medical)miRNAMyelogenous Leukemia-CellsExtracellular vesicles; miRNA; cancer cellsTumor microenvironmentExosome-Mediated transferbusiness.industryCancerProteinsmedicine.diseaseMicrornasMicroRNAs030104 developmental biologyOncologyTumor progressionCancer cellcancer cellsCancer researchDisease ProgressionHuman medicineExtracellular vesiclebusinessMicrovesiclesTargeted oncology
researchProduct